Universal flu vax for 50-64 year-olds cost effective in Australia

  • PDF / 143,093 Bytes
  • 1 Pages / 623.591 x 841.847 pts Page_size
  • 48 Downloads / 215 Views

DOWNLOAD

REPORT


) per: Case of ILI averted Hospitalisation averted Death averted Life-year saved QALY gained

Governmental

Societal

Healthcare payer

7589 20 228

2824 7527

3017 8041

264 992 17 289 22 408

98 602 6433 8338

105 343 6873 8908

Probabilistic sensitivity analyses revealed that, based on a maximum cost-effectiveness threshold of $A50 000/QALY gained, > 99% of simulations from all perspectives were cost-effective in this age group. The risk of death due to influenza and the proportion of patients at high-risk (including patients with chronic diseases and those with weakened immune systems) were the most influential factors in these analyses. * see PharmacoEconomics and Outcomes News 487 p5; 801018655 and PharmacoEconomics and Outcomes News 499 p3; 801017490 ** CSL Biotherapies, Sanofi Pasteur and Solvay Pharmaceuticals provided funding for this project. Newall AT, et al. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 26: 2142-2153, No. 17, 801102205 16 Apr 2008

1173-5503/10/0551-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 19 Apr 2008 No. 551

1